Liminatus Pharma, Inc. (LIMNW) stock
LIMNWNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as LIMN
$0.04+0.00 (0.00%)
Close on Oct 30, 2026Market cap $189.39MP/E –Yield –
Liminatus Pharma r&d expenses
Research and development expenses are spending on new products and technology.
Liminatus Pharma's R&D Expenses for the twelve months ending Dec 31, 2024 was $2.69M. For fiscal 2024 it was $2.69M.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $2.69M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $600.00K | -16.0% |
| Q1 FY2026 | Mar 31, 2026 | $400.00K | – |
| Q4 FY2024 | Dec 31, 2024 | $0 | – |
| Q3 FY2024 | Sep 30, 2024 | $357.07K | – |
| Q2 FY2024 | Jun 30, 2024 | $714.13K | – |